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Abstract A variety of human disease conditions are
associated with chronic intestinal disorders or enteropathies
that are characterized by intestinal inflammation, increased
gut permeability, and reduced capacity to absorb nutrients.
Such disruptions in the homeostasis of the gastrointestinal
(GI) tract can lead to symptoms of abdominal pain and dis-
comfort, bloating, abnormal bowel function, and malab-
sorption of nutrients. While significant advances have been
made in understanding the factors that influence the complex
and fragile balance between the gut microbiota, intestinal
epithelial cell integrity, and the underlying immune system,
effective therapies for restoring intestinal balance during
enteropathy are still not available. Numerous studies have
demonstrated the ability of oral immunoglobulins to improve
weight gain, support gut barrier function, and reduce the
severity of enteropathy in animals. More recently, studies in
humans provide evidence that serum-derived bovine
immunoglobulin/protein isolate is safe and improves
nutritional status and GI symptoms in patients with enter-
opathy associated with irritable bowel syndrome or infection
with the human immunodeficiency virus. This review
summarizes studies showing the impact of enteropathy on
nutritional status and how specially formulated bovine
immunoglobulins may help restore intestinal homeostasis
and nutritional status in patients with specific enteropathies.
Such protein preparations may provide distinct nutritional
support required for the dietary management of patients who,
because of therapeutic or chronic medical needs, have lim-
ited or impaired capacity to digest, absorb, or metabolize
ordinary foodstuffs or certain nutrients, or other special
medically determined nutrient requirements that cannot be
satisfied by changes to the normal diet alone.
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Introduction
The unique structure of the intestinal epithelium provides
both a vast surface area for nutrient absorption and a barrier
mechanism that regulates the trafficking of macromole-
cules between the lumen of the intestine and the systemic
circulation [1–3]. The effectiveness of the gut barrier is
largely governed by intestinal permeability and mucosal
immune defenses, the latter being provided mainly by the
gut-associated lymphoid tissue (GALT). Permeation of
solvents and solutes across the mucosal layer is closely
regulated and mainly depends on the integrity of tight
junction proteins (e.g., occludins, claudins) and scaffolding
proteins that span the paracellular space [2]. Meanwhile,
the lumen of the GI tract is occupied by a complex
assortment of microbial species, the gut microbiota, which
exists in a symbiotic relationship with the intestinal epi-
thelium and mucus layer by providing protection against
infection [3, 4], metabolizing dietary compounds and
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ingested foreign compounds (xenobiotics), and producing
short chain fatty acids (SCFA) and other metabolites that
support barrier function and energy metabolism.
Unfortunately, a variety of factors, both host-related and
environmental, can disrupt intestinal homeostasis and lead to
development of intestinal disorders or enteropathies. While the
exact pathophysiologic mechanisms leading to enteropathy are
not well understood, factors that appear to be involved include
genetics, diet, alterations in the intestinal microbiota, host
immune status, and exposure to external antigens, toxins, or
other environmental insults (including infection). Such factors
act singly or in combination to trigger changes in the intestinal
mucosa or the gut microbiota that leads to a prolonged cycle of
immune dysregulation, gut barrier dysfunction, and malab-
sorption of important macro- and micro-nutrients. Nutrient
malabsorption is likely to play a pivotal role in amplifying and
prolonging this cycle of events due to adverse effects on the
health and function of gut epithelial and immune cells and the
composition of the intestinal microbiota. Unique nutritional
interventions that help manage this harmful cycle of events by
improving nutrient absorption and nutritional status may rep-
resent a novel strategy to help restore functional gut homeo-
stasis and manage enteropathy in patients.
It is well established that plasma-derived protein con-
centrates (PPC) from bovine, porcine, and other sources,
when added to the diets of several species of animals, lead to
improvements in appetite, weight gain, intestinal growth,
and gut barrier function in a number of intestinal disorders [5,
6]. More recently, preliminary studies with a serum-derived
bovine immunoglobulin/protein isolate (SBI), specially
formulated to increase immunoglobulin levels, have dem-
onstrated promising results in the management of the
enteropathy in patients with chronic loose and frequent
stools in such conditions as diarrhea-predominant irritable
bowel syndrome (IBS-D) and human immunodeficiency
virus (HIV) infection as a medical food administered under
physician supervision [7, 8]. This review summarizes current
understanding about the impact of enteropathy on host
nutritional status and how specially formulated immu-
noglobulin-containing protein preparations may support
existing therapeutic strategies and fulfill a distinct nutritional
requirement in patients with chronic intestinal disorders by
helping to restore nutrient absorption and functional
homeostasis in the GI tract, a requirement of medical foods.1
Etiology and Clinical Features of Enteropathy
The intestinal damage that is associated with enteropathy is
typically characterized by blunting of intestinal villi, crypt
hyperplasia, and increased intra-epithelial lymphocytes that
leads to reduced absorptive capacity and increased gut
permeability. The breakdown in intestinal barrier function
can facilitate translocation of microbes or microbial com-
ponents across the intestinal wall, leading to chronic sys-
temic inflammation that may have additional adverse
effects on patient health. Symptoms reported by patients
with enteropathy vary depending on the etiologic factors
involved, but commonly include chronic fatigue, abdomi-
nal pain, intestinal discomfort, nausea, bloating, and
abnormal bowel function (e.g., acute or chronic diarrhea,
urgency, constipation).
Perhaps the most widely recognized form of enteropathy
is known as ‘‘environmental enteropathy,’’ which refers to
a spectrum of disorders that occurs in people living in
unhygienic conditions [9]. Although the precise cause of
environmental enteropathy is not known, it is thought to
involve repeated, often subclinical episodes of GI infec-
tions which, together with suboptimal nutrition and altered
intestinal microbiota, lead to chronic enteric T cell-medi-
ated inflammation. Enteropathy can also occur following
intake of nonsteroidal anti-inflammatory drugs (NSAIDS)
through inhibition of cyclooxygenase (COX) activity or
direct damage of epithelial cells or disruption of intercel-
lular junctions, leading to increased mucosal permeability,
antigen uptake, and immune activation [10, 11]. Other
important disease states or conditions where enteropathy
commonly occurs include HIV infection [12, 13], irritable
bowel syndrome (IBS) [14, 15], inflammatory bowel dis-
ease (IBD), celiac disease [16], and different forms of
cancer or cancer treatment. A number of studies have
reported that HIV-associated enteropathy and IBS, condi-
tions associated with decreased barrier function, inflam-
matory damage, and malabsorption, where a causative
pathogen cannot be identified, may involve dysregulation
of GI motility, altered intestinal microbiota, immune acti-
vation, increased gut permeability, alterations in trypto-
phan metabolism, or the gut–brain axis [12–15, 17–19].
The enteropathy associated with these disease states affects
a high percentage of patients and leads to incapacitating
symptoms, low quality of life, and substantial healthcare
costs. Unfortunately, truly effective therapeutic options
aimed at the enteropathy associated with various disease
states are not available, and recent attempts to launch new
treatment options have been disappointing.
Etiology of Enteropathy
The pathophysiologic mechanisms leading to enteropathy
are not well understood but may involve the effects of host
diet or genetics, exposure to specific luminal antigens or
toxins, dysregulated immune responses, or changes in the
composition of the intestinal microbiota [4, 17, 20]. An
1 The Orphan Drug Act and Amendments of 1988 [21 U.S.C.
§ 360ee(b)(3)] and current FDA regulations/guidance.
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accumulating body of evidence from both preclinical and
clinical studies indicates that such factors work individu-
ally or in combination to trigger a persistent cycle of
altered gut microbiota, immune activation, leading to
intestinal inflammation and gut barrier function that ulti-
mately leads to malabsorption of important macro- and
micro-nutrients (Fig. 1).
Altered Gut Microbiota
Alterations in the intestinal microbiota have been postu-
lated to play a role in the etiology of enteropathy. For
example, infectious gastroenteritis is accompanied by
changes in GI microflora and immune activation and is
widely recognized as a predisposing factor for IBS [21].
Postinfectious IBS occurs in 6–17 % of patients [22, 23].
Antibiotic use has also been recognized for a role in pre-
disposing patients to IBS or exacerbating symptoms of IBS
enteropathy [24]. Several studies have also reported dif-
ferences in the composition of the intestinal microbiota in
patients with IBS compared with healthy individuals [21,
25–27]. Likewise, the early phases of HIV infection have
been associated with altered gut microbiota, damaged
mucosal barrier, and intestinal inflammation [28]. Recent
reports also suggest that levels of certain components of the
resident microbiota are reduced in patients with chronic
inflammatory disorders [29, 30] and may play a role in
regulating inflammation and gut barrier function [31, 32].
For example, Akkermansia muciniphila, a mucin-degrading
bacterium found in the mucus layer of healthy humans, has
been associated with improvements in gut barrier function,
metabolic profile, and decreases in endotoxemia [33].
Faecalibacterium prausnitzii, another purported beneficial
commensal bacterium, was shown to be associated with
increased production of IL-10 while significantly decreas-
ing IL-12 and IFN-c in peripheral blood mononuclear cells
[32]. Levels of F. prausnitzii are found in low abundance in
patients with Crohn’s Disease [34], colorectal cancer, and
IBS [25], adding further support to its role as a beneficial
commensal. Whether the dysbiosis observed in gut mic-
robiota is a secondary phenomenon or truly causal in these
diseases and conditions remains to be determined.
Inflammation and Gut Barrier Dysfunction
There is increasing evidence that the reciprocal effects of
inflammation and gut barrier dysfunction play a role in the
etiology of various human diseases or conditions that are
associated with enteropathy [3, 17, 35]. For example,
intestinal infections or other changes to the intestinal
microbiota can cause aberrant or uncontrolled local
immune responses that lead to transient or chronic
inflammation, which is known to impact intestinal structure
and function [17, 36] and may participate in the etiology of
enteropathy. Intermittent or even minor inflammation can
lead to increased production and release of pro-inflamma-
tory interleukins and cytokines such as TNF-a, IFN-c [1,
37], which have been shown to affect intestinal function
[17, 36] and increase paracellular permeability by
impacting the expression or degradation of claudin and
occludin tight junction proteins [38, 39]. Conversely, cer-
tain anti-inflammatory cytokines such as IL-10 and TGF-b
appear to maintain tight junction barrier and protect against
intestinal inflammation [1]. Other examples of disease
states where molecular changes in tight junctions are
believed to be associated with inflammation, diarrhea, and
gut barrier dysfunction include chemotherapy during can-
cer [40] and IBS [37].
Alternatively, infections or exposure to other environ-
mental factors can directly increase the porosity of the tight
junction barrier. This increase in paracellular penetration of
luminal substances leads to overexposure to pro-inflam-
matory antigens (e.g., intact bacteria, lipopolysaccharides,
food antigens, xenobiotics) with associated release of pro-
inflammatory cytokines and recruitment of inflammatory
cells [1, 4, 41] that can further exacerbate mucosal damage
and gut permeability [42].
Fig. 1 Enteropathy is
associated with nutrient
malabsorption caused by a
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Immune Dysregulation
Recent evidence from genome-wide association studies in
IBD support the hypothesis that certain genetic mutations
may lead to inappropriate regulation of immune responses,
which could impact gut barrier function and lead to
enteropathy. For example, mutations that affect the func-
tion of certain pattern recognition receptors such as NOD2/
CARD15, expressed in immune cells with important
functions in innate immunity, may result in defective
down-regulation of pro-inflammatory cytokines that nor-
mally occurs during chronic NOD2 stimulation [43]. Other
such genetic studies have shown associations between
Crohn’s disease and mutations in genes related to IL-10
[44], a potent anti-inflammatory cytokine, and IL-23 [45], a
pro-inflammatory cytokine that serves as an important
downstream mediator of inflammation.
Impact of Enteropathy on Nutritional Status
Alterations in gut barrier function, microbiota, and immune
activation that occur during enteropathy can also lead to
malabsorption of nutrients and, depending on severity, lead
to chronic undernutrition. For example, an overzealous
inflammatory response with local involvement of lym-
phocytes, mast cells, and neutrophils may result in the
release of proteases, prostaglandins, leukotrienes, and other
eicosanoids, and oxygen free radicals. These inflammatory
mediators can impact the expression of nutrient transport
proteins [46, 47], as well as tight junction proteins [1, 48],
and cause microscopic damage which collectively leads to
gut barrier dysfunction and malabsorption of water, elec-
trolytes, and key nutrients. Altered bowel function
(increased motility, diarrhea, etc.) during enteropathy can
also impact nutritional status by interfering with absorption
of vital nutrients and electrolytes or by causing changes in
feeding patterns in an attempt to avoid symptoms. Acute or
chronic malabsorption can lead to atypical vitamin levels,
maldigestion or malabsorption of carbohydrates and fats,
altered synthesis and reabsorption of bile acids, or abnor-
mal metabolism of key amino acids like tryptophan, all of
which can contribute further to symptoms. Stimulation of
the immune system also shifts available energy and nutri-
ents from growth and other productive functions and
diverts them to support the immune system [49, 50].
The microscopic damage from inflammation or other
environmental insults can also develop into macroscopic
injury (erosions, ulcers, etc.) that appears histologically as
villous blunting, crypt hyperplasia, or villous atrophy with
inflammatory infiltrate. Enterocytes may be directly impac-
ted through changes in cellular differentiation with com-
promised absorptive and secretory function. Deficiencies of
brush border disaccharidases at the mucosal membrane may
occur and lead to maldigestion and intolerance to various
dietary sugars. Disaccharide malabsorption can lead to
bacterial fermentation with production of SCFAs and gas
and changes in the composition of the microbiota, contrib-
uting further to symptoms [51]. Injury of enterocytes may
alter gut permeability and predispose to development of a
protein-losing enteropathy. Moreover, bacteria may com-
pete with the host for protein and lead to the production of
ammonia [52]. Deconjugation of bile acids in the proximal
gut causes malabsorption of fat and lipophilic vitamins (A,
D, E) and leads to the production of lithocholic acid, which is
poorly absorbed and may be directly toxic to enterocytes
[53]. While the impact of nutrients on gut epithelial function
is not completely understood, it is possible that malabsorp-
tion of specific nutrients can compromise the ability to
overcome the intestinal damage that occurs with
enteropathy.
Host genetics can also impact the efficiency of nutrient
processing that occurs in individuals with disease states
associated with enteropathy. Dozens of mutated gene loci,
for example, have been implicated in IBS [54] with pos-
sible effects on intestinal permeability, tryptophan metab-
olism [18], or the synthesis and metabolism of bile acids
[55]. Modifications in tryptophan, serotonin, and bile acid
metabolism, as well as alterations in the host microbiome,
have been implicated in causing or exacerbating many of
the symptoms associated with IBS-D [18, 19]. Likewise,
perturbations in the intestinal microflora that occur in dis-
ease states with enteropathy also have the ability to impact
host nutritional status including fluid balance. Both diet and
alterations in the microbiota can impact luminal concen-
tration of intestinal SCFAs [56], which act as an energy
source for the host, exert effects on the cytokine production
profile of helper T cells [57], and promote intestinal epi-
thelial barrier function [58, 59]. The intestinal microbiota
can synthesize several vitamins that play important roles in
microbial and host metabolism, including cobalamin
(vitamin B12), vitamin B6, pantothenic acid (vitamin B5),
niacin (vitamin B3), biotin, tetrahydrofolate, and vitamin
K. The microbiota also affects the absorption of key min-
erals such as iron, which serves as an essential micronu-
trient for bacteria and impacts immune functions. Finally,
small intestinal bacterial overgrowth (SIBO) can interfere
with the metabolism and absorption of carbohydrates,
proteins, lipids, and vitamins because of increased levels of
bacteria in the small intestine.
Clearly, exposure to noxious environmental factors that
lead to the changes in the gut microbiota or mucosal lining
associated with enteropathy can also impact functional
digestion and absorption of key nutrients important for
supporting health and recovery from disease. Patients with
enteropathy may have a distinct nutritional requirement for
16 Dig Dis Sci (2015) 60:13–23
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a specially formulated dietary compound that restores
functional homeostasis in the gut by managing the chronic
impact of gut barrier dysfunction, altered intestinal mic-
robiota, or dysregulated mucosal immune activation.
Dietary Requirement for Oral Immunoglobulins
to Manage Enteropathy
Colostrum and breast milk, the sole source of nutrition for the
neonate, contain immunoglobulins as well as a number of
important bioactive factors and nutrients. Such factors, along
with early exposure to external antigens and bacteria, are
critical for providing passive protection from infections,
establishing the intestinal microbiota, and stimulating mat-
uration of the infant’s mucosal immune system [60–62].
Immunoglobulins play a particularly prominent role in pro-
viding the gastrointestinal health and developmental benefits
of human milk and colostrum, along with other factors such
as regulatory cytokines, growth factors, lysozyme, lacto-
ferrin, and oligosaccharides [60]. A large body of evidence
also indicates that serum- or plasma-derived bovine immu-
noglobulin preparations fulfill a similar nutritional need by
helping to manage the harmful effects of enteropathy by
promoting gut homeostasis [5–8, 66, 67].
Safety and Nutritive Benefits of Oral Immunoglobulins
The recognition that colostrum is essential for the health
and early survival of ruminant neonates led to the devel-
opment of commercial plasma-derived protein concentrates
which contain immunoglobulins that have been used for
decades in animal husbandry to promote growth, prevent
infections, and modulate intestinal inflammation in young
immune-compromised animals. Numerous studies have
evaluated the safety and nutritive benefits of commercial
serum or plasma protein preparations in piglets undergoing
early weaning, a condition known to induce impairment in
intestinal epithelial barrier function, as well as several
preclinical models of intestinal inflammation (Table 1). A
review of 75 nonclinical studies in 43 different publications
[6] indicates that bovine immunoglobulin-containing pro-
tein concentrates (PPC’s) are safe and improve appetite,
weight gain, and intestinal barrier function in weaning pigs.
Replacement of several high-quality protein sources (e.g.,
meat extracts, soy, pea, and potato protein isolates, skim-
med milk, whey protein, fishmeal) with immunoglobulin
protein mixtures similar to the composition of SBI led to
superior weight gain and feed intake in weaned piglets,
suggesting that distinct proteins in SBI were involved in
stimulating beneficial digestive and metabolic effects [5].
Nonclinical studies have found that as much as 50 % of
IgG from SBI survives transit through the stomach, while
5–10 % survives transit through the entire intestinal tract
[63, 64].
The safety and nutritive benefits of oral immunoglobu-
lins have also been evaluated in clinical studies involving
both pediatric and adult subjects using a commercial form
of SBI2 that contains over 90 % protein (by weight), over
50 % of which are immunoglobulins, (mainly IgG). The
remaining proteins and peptides reflect the composition of
plasma and are similar to proteins present in colostrum and
milk, and the preparation does not contain milk ingredients
such as lactose, casein, or whey, so adverse reaction rates
would be expected to be minimal. However, SBI contains
beef proteins, so patients who have an allergy to beef
should not take SBI. The rigorous process used to prepare
commercial forms of SBI meets strict industry standards of
current good manufacturing practices (cGMPs) to ensure
that finished products do not become contaminated with
infectious agents, including the bovine spongiform
encephalitis (BSE) agent. In addition, SBI has been self-
affirmed as generally recognized as safe (GRAS) with no
safety-related questions by the US Food and Drug
Administration (FDA) for doses up to 50 g/d. SBI has not
yet been tested in pregnant or nursing mothers or immu-
nocompromised individuals, so use in such patients should
be at the discretion of the patients’ physician.
In a human study of SBI tolerability and digestion, intact
bovine IgG was detected in the feces of volunteers but not
serum (n = 12), providing evidence that bovine immuno-
globulin is not absorbed from the intestinal lumen into the
circulation [65]. Volunteers were administered 10 g of SBI
orally and blood samples were obtained at various time
points, which showed elevated plasma levels of total amino
acids and leucine from 1 to 2 h after SBI administration. This
suggests at least partial digestion of the protein mixture to the
amino acid level during transit through the intestine. Sur-
vival of the bovine IgG fraction through the GI tract suggests
that oral SBI remains biologically active to manage chronic
loose and frequent stools in conditions such as IBS-D and
HIV-associated enteropathy. Subjects then consumed 5 g of
SBI daily for 2 weeks and completed daily diaries for general
health and adverse events (AEs). No serious AEs were
reported by test subjects. The following AEs were reported:
increased urination (3); stomach cramps (3); fatigue (2);
headache (2); sore throat, softened stools, nausea, constipa-
tion, and irritability (1 each) [65].
In a randomized and controlled, community-based
intervention study, the effects of dietary supplementation
2 EnteraGam is a serum-derived bovine immunoglobulin/protein
isolate (SBI) specially formulated for use as a medical food to be used
under medical supervision for patients with limited or impaired
capacity to ingest, digest, absorb, or metabolize ordinary foods or
certain nutrients because of therapeutic or chronic medical needs and
for management of chronic loose and frequent stools.
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with bovine serum concentrate (22 % IgG, w/w) and/or
multiple micronutrients (MMN) on growth, morbidity, and
micronutrient status were evaluated in healthy children
[66]. Children were enrolled at 6 to 7 months of age
(n = 259) and randomized to receive 1 of 4 maize-based
study products daily for up to 8 months: whey protein
concentrate WPC (control group), bovine serum concen-
trate (BSC), WPC plus multiple micronutrients, or BSC
plus multiple micronutrients. One hundred thirty-two
children (132; 51.0 %) finished the full 8 months of study
observation. There were no significant differences reported
in the rate of dropouts between treatment groups during the
study and the rate of early dropouts did not correlate with
study product consumed or prevalence/incidence of mor-
bidity. While not significant, trends were observed for
improvements in weight gain and lean body mass.
In another study, the acceptability, safety, and digest-
ibility of spray-dried bovine plasma proteins including
immunoglobulins were evaluated in young Peruvian chil-
dren (9–25 months of age) recovering from severe protein-
energy malnutrition [67]. A control diet prepared from rice,
milk, vegetable oil, and sugar was compared with 2 study
diets where a bovine plasma protein mixture replaced
either 25 or 50 % of the milk protein in the control diet.
Fractional absorption of dietary lipid and of total energy
increased significantly in relation to the amount of SBI in
the diet, as shown by decreased fecal fat and energy con-
tent. Diets containing greater amounts of plasma protein
mixture with immunoglobulins and reduced levels of milk
protein led to progressive reductions in wet and dry stool
weights and greater fat absorption compared with the
control diet, leading authors to suggest that the plasma
Table 1 Effects of serum-derived immunoglobulin preparations on intestinal barrier function and immune response
Species Model/Indication Impact of dietary administration of immunoglobulin preparations References
Pig Post-weaning Reduced TNF-a in the colon
Reduced IFNc levels in the ileum and colon day 7, but not day 14 PW
Peace et al.
[68]
Pig Post-weaning Reduced colonic paracellular permeability
Reduced ileal permeability
Fewer lamina propria cells in ileum and colon
Reduced transepithelial electrical resistance in the colon–improved tight junction
Significantly improved fecal scores
Peace et al.
[68]
Rotavirus infection Significantly reduced clinical signs of diarrhea
Significantly greater intestinal mucosal protein and lactase activity
Corl et al. [70]
Infection by ETEC K88 Reduced expression of TNF-a and IL-8 in the gut
Decreased inflammatory cell infiltration and mucosal damage
Increased crypt depth, reduced intestinal expression of proinflammatory TNF-a
and IL-8
Bosi et al. [71]
Rat Exposure to SEB Improved ion transport function, as measured by reductions in the potential
difference across the jejunum and Na–K-ATPase activity
Improved mucosal permeability (dextran flux and HRP paracellular flux)
Perez-Bosque
et al. [48]
Rat SEB Prevented the SEB-induced increase in IFNc, IL-6, and LTB4 in Peyer’s patches
and in the mucosa




Reduced SEB-induced increase in cytotoxic lymphocyte populations of cd-T




Mouse Mdr1-/- knockout mouse model
of spontaneous colitis
Reduced the percentage of activated Th lymphocytes
Reduced INFc and TNFa expression in the colon
Significantly reduced the expression of cytokines IL-2 and IL-17, chemokines
MCP-1 and MIP-1b, and iNOS in the mucosa
Moreto´et al.
[72]
Mouse 2 % DSS-induced IBD model Reduced elevation of IL-1a, IL-4, IL-6, IL-10, MCP-1, and KC Jiang et al.
[73]
TNFa tumor necrosis factor a, IFNc interferon-c, ETEC K88 enterotoxigenic Escherichia coli K88 strain, IL-8 interleukin-8, SEB Staphylococcus
aureus enterotoxin B, Na–K-ATPase sodium–potassium adenosine triphosphatase, HRP horse radish peroxidase, IL-6 interleukin-6, LTB4
leukotriene B4, IL-10 interleukin-10, TGFb transforming growth factor b, IL-17 interleukin 17, MCP-1 monocyte chemotactic protein 1, MIP-1b
macrophage inflammatory protein, iNOS inducible nitric oxide synthase, DSS dextran sodium sulfate, IL-1a interleukin-1a, IL-4 interleukin-4,
KC keratinocyte-derived cytokine
18 Dig Dis Sci (2015) 60:13–23
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protein mixtures were more digestible or enhanced recov-
ery from malnutrition. There was also a trend toward
superior nitrogen and carbohydrate absorption with
increasing amounts of plasma protein.
Ability to Restore Functional Homeostasis of the Gut
Barrier
The ability of serum protein preparations like SBI to
restore intestinal barrier function and nutrient absorption,
or essentially functional homeostasis, has been evaluated in
a number of preclinical studies (Table 1). Studies using
animal models and ex vivo test systems have evaluated
tight junction protein expression in the epithelial barriers of
early-weaned piglets fed diets containing porcine plasma
protein with high levels of immunoglobulins [68]. Intesti-
nal barrier function was shown to be improved in piglets
fed diets containing porcine plasma protein as indicated by
an increased transepithelial electrical resistance and sig-
nificant reductions in colonic 14C-inulin permeability on
day 7 post-weaning and reduced ileal permeability of 3H-
mannitol and 14C-inulin on day 14 [68]. Immunofluores-
cence staining demonstrated that claudin-1 was more
highly expressed and localized to tight junctions in animals
fed porcine plasma protein, compared with the diffuse low-
signal staining observed in control tissues at 7-day post-
weaning [68]. Other studies have demonstrated the ability
of plasma protein preparations to directly improve gut
permeability, prevent antigen translocation across damaged
tight junctions via direct binding and steric hindrance, and
have an impact on tight junction protein expression [48,
69]. Together, these studies demonstrate that serum protein
preparations containing immunoglobulins are able to
manage the negative effects of antigen/toxin challenge on
the intestinal epithelial barrier.
The impact of SBI on markers of intestinal absorption,
GI symptom scores, and quality of life measures have also
been evaluated in two clinical studies involving patients
with HIV-associated enteropathy or IBS-D. In an open
label study by Asmuth et al. [8], eight subjects with HIV-
associated enteropathy showed improvements in GI
symptoms with reduced bowel movements per day
(p \ 0.008) and improvements in stool consistency
(p \ 0.008). Seven of the eight subjects also showed
increased uptake of D-xylose suggesting improved
absorption of nutrients. Another randomized, double-
blind, placebo-controlled study was conducted in subjects
with IBS-D [7] to investigate the impact of SBI on
improving gastrointestinal (GI) symptom scores and
quality of life (QoL). Study subjects consuming SBI
reported a significant decrease in the number of days with
GI symptoms (e.g., abdominal pain, flatulence, bloating,
urgency, and loose stools), suggesting improved GI
function with implications for nutritive benefits. Soy
protein administered at the same dose did not statistically
improve any GI symptoms. These results demonstrate that
SBI, a specially formulated bovine IgG protein prepara-
tion, provides for a distinct nutritional requirement in
enteropathy patients who have a limited or impaired
capacity to ingest, digest, absorb, or metabolize ordinary
foodstuffs or certain nutrients, and those with fluid
imbalance due to chronic loose and frequent stools (i.e.,
IBS-D and HIV-associated enteropathy).
Impact on Immune Balance
Studies on the effects of bovine immunoglobulin isolates
(PPC or SBI) on inflammation in the GI tract have pri-
marily come from preclinical models in which animals
were challenged by infection or exposure to bacterial tox-
ins (Table 1). For example, Corl et al. [70] found PPC to be
effective at reducing diarrhea, improving intestinal recov-
ery and maintaining growth in piglets infected with rota-
virus. Bosi et al. [71] investigated the impact of PPC on
growth and intestinal inflammation in pigs challenged with
enterotoxigenic Escherichia coli K88 (ETEC K88). When
compared to a diet based on fish protein, pigs infected with
ETEC K88 and fed PPC showed higher calorie intake and
daily weight gain, less intestinal mucosal damage (ulcera-
tion, edema) and inflammatory cell infiltration, and reduced
expression of pro-inflammatory cytokines. Oral SBI has
also been shown to reduce the expression of pro-inflam-
matory cytokines (e.g., TNF-a, IL-6) and alter the lym-
phocyte response of immune challenge in weaned piglets
[68], and experimental models of intestinal inflammation in
mice [72, 73], rats [74, 75], and pigs [71]. These results
from experimental studies suggest that dietary PPC pro-
vides anti-inflammatory effects that benefits recovery of
intestinal barrier function.
In the trial involving patients with HIV-associated
enteropathy mentioned earlier, SBI significantly increased
mucosal CD4? lymphocyte densities over 8 wks, but had
no effect on circulating CD4? counts [8]. In addition, a
marker for enterocyte damage, intestinal fatty acid protein
(I-FABP), initially rose in 7/8 subjects after 8 weeks, but
then fell below baseline in 4/5 subjects who continued
taking SBI for 40 additional weeks, suggesting that
inflammation-based destruction of enterocytes had been
ameliorated. Monocyte chemoattractant protein-1 (MCP-1)
levels were also negatively correlated with lamina propria
CD4? density, suggesting a commonality of systemic
inflammation and mucosal immunity. In addition, inflam-
mation-induced tissue remodeling matrix metallo-protein-
ases decreased over time also suggesting a dampening of
inflammation and tissue-specific remodeling in the
intestine.
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Effects on Microbiota Balance and Endotoxin Binding
Immunoglobulins may also impart the nutritive benefits of
SBI by impacting the growth and maintenance of the
normal intestinal microbiota. Because SBI is prepared from
pooled plasma obtained from thousands of bovine donors,
the immunoglobulins in SBI are directed at a wide array of
foreign antigens and microbial organisms. This includes
IgG that is specific for highly conserved microbial antigens
that allows direct binding to microbial cell wall or other
microbial components and interferes with their ability to
enter or damage intestinal epithelial cells. Studies have
shown that the IgG, IgA, and IgM contained in SBI bind to
bacterial endotoxins and other microbial antigens [76, 77].
It is possible that binding of endotoxins or other pro-
inflammatory antigens may interfere with the signaling
mechanisms on innate immune cells and prevent down-
stream signaling cascades that lead to production of pro-
inflammatory cytokines and inflammation.
The effect of SBI on restoring imbalances of microbiota
was also studied in patients with HIV-associated enterop-
athy [78, 79]. While Firmicutes and Bacteriodales were
found to be the dominant phyla in stool samples of all 8
HIV? patients, when SBI was administered, pro-inflam-
matory gammaproteobacteria tended to decrease from
levels of 0.70 to 0.12 % [78]. Clostridium spp. tended to
decrease from 6.5 to 3.4 % in stool and correlated with
duodenal CD3?/CD4? density (r = -0.63; p \ 0.01).
Ruminococcus spp. and the Bacteroidetes/Firmicutes ratio
also increased in 6/8 subjects, an effect that has been
implicated in contributing to better calorie utilization from
the diet [80, 81]. These results suggest that some compo-
nent in SBI, perhaps the IgG fraction, may be effective in
normalizing gut bacteria with potential implications for
improving nutrient utilization.
Conclusions
Most therapies that are currently used in patients with
enteropathy are aimed at lessening symptoms rather than
managing the underlying causes of the disorder. This may
be due to the complex mechanisms involved in the path-
ophysiology of enteropathy, which may serve to explain
why no single treatment has been shown to be effective in
patients with enteropathy. A variety of preclinical studies
and clinical trials have demonstrated that special formu-
lations of serum-derived immunoglobulin/protein isolates
(SBI) improve nutritional status, support gut barrier func-
tion, and manage enteropathy. Immunoglobulins appear to
be unique, compared with multiple other protein sources, in
terms of providing distinctive nutrition required to manage
enteropathy in these studies. Possible ways that oral
immunoglobulins might work to restore gut homeostasis
during enteropathy include ‘‘immune exclusion’’ to prevent
contact between bacteria or bacterial components and gut
epithelium or immune cells, shaping the gut microbiota, or
Table 2 Potential roles for how oral immunoglobulins may con-
tribute to protection of mucosal surfaces and maintaining intestinal
homeostasis



















motility) or toxins and
interfering with the


















in response to LPS,


























access to the lamina






























20 Dig Dis Sci (2015) 60:13–23
123
modulating immune responses and mucosal damage [82]
(Table 2).
Specially formulated immunoglobulin sources like SBI
appear to act through a multifaceted mode of action that
serves to bind and neutralize pro-inflammatory microbial
components, support a beneficial gut microbiota, manage
gut barrier function, and maintain immune balance. These
effects collectively serve to improve and maintain nutrient
utilization, including water balance, to aid in the manage-
ment of enteropathy in patients with chronic loose and
frequent stools in conditions like IBS-D and HIV-infected
patients. Taken together, results from clinical and non-
clinical studies with SBI reveal a distinct nutritional
requirement for immunoglobulins for the purpose of
restoring functional homeostasis to aid in the management
of enteropathy.
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